NEW YORK, July 24, 2025 /PRNewswire/ -- GNT Pharma, a late-stage biopharmaceutical company with operations in Seoul and New York, today announced its IND Application to commence Global Phase 3 ...
YONGIN, South Korea--(BUSINESS WIRE)--GNT Pharma Inc. today reports positive top-line results from a phase II, double-blind, randomized, placebo-controlled, multi-center study assessing the safety and ...
** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Multinational Phase 3 Clinical Trial protocols ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results